SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    F. Rencz, P. Holló, S. Kárpáti, M. Péntek, É. Remenyik, A. Szegedi, O. Balogh, E. Herédi, K. Herszényi, H. Jókai, V. Brodszky, L. Gulácsi, Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity, Journal of the European Academy of Dermatology and Venereology, 2015, 29, 3
  2. 2
    E. Salahadeen, C. Torp-Pedersen, G. Gislason, P.R. Hansen, O. Ahlehoff, Nationwide population-based study of cause-specific death rates in patients with psoriasis, Journal of the European Academy of Dermatology and Venereology, 2015, 29, 3
  3. 3
    Sylvie Mireille Franken, Birgit Witte, Stan Pavel, Thomas Rustemeyer, Psoriasis and daily low-emission phototherapy: effects on disease and vitamin D level, Photodermatology, Photoimmunology & Photomedicine, 2015, 31, 1
  4. 4
    Marisa Kardos Garshick, Alexa Boer Kimball, Psoriasis and the Life Cycle of Persistent Life Effects, Dermatologic Clinics, 2015, 33, 1, 25

    CrossRef

  5. 5
    Caitriona Ryan, Brian Kirby, Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities, Dermatologic Clinics, 2015, 33, 1, 41

    CrossRef

  6. 6
    Lluís Puig, Robert Strohal, Joanne Fuiman, Ronald Pedersen, Annette Szumski, Andrew S. Koenig, Deborah Robertson, Heinz Drexel, Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment*, Journal of Dermatological Treatment, 2014, 25, 6, 470

    CrossRef

  7. 7
    Jeremy Hugh, Abby S. Van Voorhees, Rajiv I. Nijhawan, Jerry Bagel, Mark Lebwohl, Andrew Blauvelt, Sylvia Hsu, Jeffrey M. Weinberg, From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies, Journal of the American Academy of Dermatology, 2014, 70, 1, 168

    CrossRef

  8. 8
    Tiago Torres, Andrea Chiricozzi, Sergio Chimenti, Rosita Saraceno, Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece, Molecular Diagnosis & Therapy, 2014, 18, 1, 93

    CrossRef

  9. 9
    J.J. Wu, L. Liu, M.M. Asgari, J.R. Curtis, L. Harrold, C. Salman, L.J. Herrinton, Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis, Journal of the European Academy of Dermatology and Venereology, 2014, 28, 10
  10. 10
    Iris Gutmark-Little, Kara N. Shah, Obesity and the Metabolic Syndrome in Pediatric Psoriasis, Clinics in Dermatology, 2014,

    CrossRef

  11. 11
    R. Strohal, B. Kirby, L. Puig, Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis, Journal of the European Academy of Dermatology and Venereology, 2014, 28, 12
  12. 12
    Tiago Torres, Nuno Bettencourt, Psoriasis: The visible killer, Revista Portuguesa de Cardiologia, 2014, 33, 2, 95

    CrossRef

  13. 13
    Tiago Torres, Nuno Bettencourt, Psoriasis: The visible killer, Revista Portuguesa de Cardiologia (English Edition), 2014, 33, 2, 95

    CrossRef

  14. 14
    Ulrich Mrowietz, Kirsten Steinz, Sascha Gerdes, Psoriasis: to treat or to manage?, Experimental Dermatology, 2014, 23, 10
  15. 15
    Sameer Shaharyar, Haider Warraich, John W. McEvoy, Ebenezer Oni, Shozab S. Ali, Adil Karim, Omar Jamal, Michael J. Blaha, Roger S. Blumenthal, Jonathan Fialkow, Ricardo Cury, Matthew J. Budoff, Arthur A. Agatston, Khurram Nasir, Subclinical cardiovascular disease in plaque psoriasis: Association or causal link?, Atherosclerosis, 2014, 232, 1, 72

    CrossRef

  16. You have free access to this content16
    C. Horreau, C. Pouplard, E. Brenaut, T. Barnetche, L. Misery, B. Cribier, D. Jullien, S. Aractingi, F. Aubin, P. Joly, M. Maître, J.-P. Ortonne, C. Paul, M.-A. Richard, Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review, Journal of the European Academy of Dermatology and Venereology, 2013, 27,
  17. You have free access to this content17
    M.-A. Richard, C. Paul, Cardiovascular morbidity, risk of cancer and alcohol abuse in psoriasis: systematic literature reviews and expert opinion, Journal of the European Academy of Dermatology and Venereology, 2013, 27,
  18. 18
    Peter Jensen, Jacob P. Thyssen, Claus Zachariae, Peter R. Hansen, Allan Linneberg, Lone Skov, Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study, International Journal of Dermatology, 2013, 52, 6
  19. 19
    Christopher K. Farmer, Paul E. Stevens, Chronic kidney disease: Psoriasis—a risk factor for chronic kidney disease?, Nature Reviews Nephrology, 2013, 10, 1, 12

    CrossRef

  20. 20
    Hsien-Yi Chiu, Ting-Shun Wang, Yung-Tsu Cho, Tsen-Fang Tsai, Etanercept use for psoriasis in Taiwan: a case series study, International Journal of Dermatology, 2013, 52, 6
  21. 21
    Tiago Torres, Rita Sales, Carlos Vasconcelos, Berta Martins da Silva, Manuela Selores, Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: Implications in cardiovascular risk factors management and primary prevention of cardiovascular disease, The Journal of Dermatology, 2013, 40, 11
  22. 22
    Jackelyn B. Golden, Thomas S. McCormick, Nicole L. Ward, IL-17 in psoriasis: Implications for therapy and cardiovascular co-morbidities, Cytokine, 2013, 62, 2, 195

    CrossRef

  23. 23
    David Siegel, Sridevi Devaraj, Anupam Mitra, Siba P. Raychaudhuri, Smriti K. Raychaudhuri, Ishwarlal Jialal, Inflammation, Atherosclerosis, and Psoriasis, Clinical Reviews in Allergy & Immunology, 2013, 44, 2, 194

    CrossRef

  24. 24
    W.-H. Boehncke, S. Boehncke, Komorbiditäten der Arthritis psoriatica, Zeitschrift für Rheumatologie, 2013, 72, 8, 779

    CrossRef

  25. 25
    Nehal N Mehta, Katherine Li, Philippe Szapary, James Krueger, Carrie Brodmerkel, Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis, Journal of Translational Medicine, 2013, 11, 1, 194

    CrossRef

  26. 26
    Howa Yeung, Joy Wan, Abby S. Van Voorhees, Kristina Callis Duffin, Gerald G. Krueger, Robert E. Kalb, Jamie D. Weisman, Brian R. Sperber, Bruce A. Brod, Stephen M. Schleicher, Bruce F. Bebo, Daniel B. Shin, Andrea B. Troxel, Joel M. Gelfand, Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis, Journal of the American Academy of Dermatology, 2013, 68, 1, 64

    CrossRef

  27. 27
    R. Fernández-Torres, S. Pita-Fernández, E. Fonseca, Psoriasis and cardiovascular risk. Assessment by different cardiovascular risk scores, Journal of the European Academy of Dermatology and Venereology, 2013, 27, 12
  28. You have free access to this content28
    M.-A. Richard, T. Barnetche, C. Horreau, E. Brenaut, C. Pouplard, S. Aractingi, F. Aubin, B. Cribier, P. Joly, D. Jullien, M. Maître, L. Misery, J.-P. Ortonne, C. Paul, Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion, Journal of the European Academy of Dermatology and Venereology, 2013, 27,
  29. 29
    Johannes Wohlrab, Gabriele Fiedler, Sascha Gerdes, Alexander Nast, Sandra Philipp, Marc A. Radtke, Diamant Thaçi, Wolfgang Koenig, Andreas F. H. Pfeiffer, Martin Härter, Michael P. Schön, Recommendations for detection of individual risk for comorbidities in patients with psoriasis, Archives of Dermatological Research, 2013, 305, 2, 91

    CrossRef

  30. 30
    Maddalena Gaeta, Serenella Castelvecchio, Cristian Ricci, Paolo Pigatto, Gabriele Pellissero, Riccardo Cappato, Role of psoriasis as independent predictor of cardiovascular disease: A meta-regression analysis, International Journal of Cardiology, 2013, 168, 3, 2282

    CrossRef

  31. 31
    E. Papadavid, K. Vlami, M. Dalamaga, S. Giatrakou, K. Theodoropoulos, S. Gyftopoulos, N. Stavrianeas, S. Papiris, D. Rigopoulos, Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role?, Journal of the European Academy of Dermatology and Venereology, 2013, 27, 7
  32. 32
    Sungwon Lee, Jashin J. Wu, A Review of the Epidemiology of Cardiovascular Comorbidities in Psoriasis, Current Dermatology Reports, 2012, 1, 1, 14

    CrossRef

  33. 33
    Yi-Ju Chen, Yun-Ting Chang, Jui-Lung Shen, Tzu-Ting Chen, Chang-Bi Wang, Chuan-Mu Chen, Chun-Ying Wu, Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: A nationwide cohort study, Arthritis & Rheumatism, 2012, 64, 6
  34. 34
    Wolf-Henning Boehncke, Sandra Boehncke, Cardiovascular Mortality in Psoriasis and Psoriatic Arthritis: Epidemiology, Pathomechanisms, Therapeutic Implications, and Perspectives, Current Rheumatology Reports, 2012, 14, 4, 343

    CrossRef

  35. 35
    Joy Wan, Katrina Abuabara, Andrea B. Troxel, Daniel B. Shin, Abby S. Van Voorhees, Bruce F. Bebo, Gerald G. Krueger, Kristina Callis Duffin, Joel M. Gelfand, Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients, Journal of the American Academy of Dermatology, 2012, 66, 3, 376

    CrossRef

  36. You have free access to this content36
    U. Mrowietz, Implementing treatment goals for successful long-term management of psoriasis, Journal of the European Academy of Dermatology and Venereology, 2012, 26,
  37. 37
    Sinéad M Langan, Nicole M Seminara, Daniel B Shin, Andrea B Troxel, Stephen E Kimmel, Nehal N Mehta, David J Margolis, Joel M Gelfand, Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom, Journal of Investigative Dermatology, 2012, 132, 3, 556

    CrossRef

  38. 38
    P. De Mozzi, G.A. Johnston, A.B. Alexandroff, Psoriasis: an evidence-based update. Report of the 9th Evidenced Based Update Meeting, 12 May 2011, Loughborough, U.K., British Journal of Dermatology, 2012, 166, 2
  39. 39
    Cheng-Che E. Lan, Ying-Chin Ko, Hsin-Su Yu, Wan-Chen Li, Ching-Shuang Wu, Yi-Wei Lu, Yi-Hsin Yang, Gwo-Shing Chen, Psoriatic patients with diabetes are prone to develop digestive organ cancers: A population-based study in Taiwan, Journal of Dermatological Science, 2012, 68, 2, 82

    CrossRef

  40. You have free access to this content40
    K. Reich, The concept of psoriasis as a systemic inflammation: implications for disease management, Journal of the European Academy of Dermatology and Venereology, 2012, 26,
  41. 41
    Alexa B. Kimball, Philippe Szapary, Ulrich Mrowietz, Kristian Reich, Richard G. Langley, Yin You, Ming-Chun Hsu, Newman Yeilding, Daniel J. Rader, Nehal N. Mehta, Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis, Journal of the American Academy of Dermatology, 2012, 67, 1, 76

    CrossRef

  42. 42
    P. De Mozzi, A.B. Alexandroff, G.A. Johnston, Updates from the British Association of Dermatologists 91st Annual Meeting, 5–7 July 2011, London, U.K., British Journal of Dermatology, 2012, 167, 2
  43. You have free access to this content43
    P. Gisondi, M. Rossini, A. Di Cesare, L. Idolazzi, S. Farina, G. Beltrami, K. Peris, G. Girolomoni, Vitamin D status in patients with chronic plaque psoriasis, British Journal of Dermatology, 2012, 166, 3
  44. 44
    Nehal N. Mehta, YiDing Yu, Rebecca Pinnelas, Parasuram Krishnamoorthy, Daniel B. Shin, Andrea B. Troxel, Joel M. Gelfand, Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events, The American Journal of Medicine, 2011, 124, 8, 775.e1

    CrossRef

  45. 45
    Janice A. Husted, Arane Thavaneswaran, Vinod Chandran, Lihi Eder, Cheryl F. Rosen, Richard J. Cook, Dafna D. Gladman, Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis, Arthritis Care & Research, 2011, 63, 12
  46. 46
    R.B. Warren, C.E. Kleyn, W.P. Gulliver, Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course, British Journal of Dermatology, 2011, 164,
  47. 47
    Alan Menter, Neil J. Korman, Craig A. Elmets, Steven R. Feldman, Joel M. Gelfand, Kenneth B. Gordon, Alice Gottlieb, John Y.M. Koo, Mark Lebwohl, Craig L. Leonardi, Henry W. Lim, Abby S. Van Voorhees, Karl R. Beutner, Caitriona Ryan, Reva Bhushan, Guidelines of care for the management of psoriasis and psoriatic arthritis, Journal of the American Academy of Dermatology, 2011, 65, 1, 137

    CrossRef

  48. 48
    Joel M Gelfand, Nehal N Mehta, Sinéad M Langan, Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II, Journal of Investigative Dermatology, 2011, 131, 5, 1007

    CrossRef

  49. 49
    U Mrowietz, K Kragballe, A Nast, K Reich, Strategies for improving the quality of care in psoriasis with the use of treatment goals – a report on an implementation meeting, Journal of the European Academy of Dermatology and Venereology, 2011, 25,
  50. 50
    Craig Leonardi, Kim Papp, Bruce Strober, Kristian Reich, Akihiko Asahina, Yihua Gu, Joseph Beason, Stephen Rozzo, Stephen Tyring, The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis, American Journal of Clinical Dermatology, 2011, 12, 5, 321

    CrossRef

  51. 51
    Erica D. Dommasch, Katrina Abuabara, Daniel B. Shin, Josephine Nguyen, Andrea B. Troxel, Joel M. Gelfand, The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials, Journal of the American Academy of Dermatology, 2011, 64, 6, 1035

    CrossRef

  52. 52
    N.M. Seminara, K. Abuabara, D.B. Shin, S.M. Langan, S.E. Kimmel, D. Margolis, A.B. Troxel, J.M. Gelfand, Validity of The Health Improvement Network (THIN) for the study of psoriasis, British Journal of Dermatology, 2011, 164, 3
  53. 53
    S.R. Feldman, Cause-specific mortality in patients with severe psoriasis, British Journal of Dermatology, 2010, 163, 3